**Supplementary Table 1**



**Table 1. Results of relevant investigations.** ALT: alanine aminotransferase; AST: aspartate aminotransferase; ALP: alkaline phosphatase; Ύ-GT: gamma-glutamyltransferase; HBsAg\_C: hepatitis B surface antigen; HIV\_Ab: anti-Human immunodeficiency virus; HCV: hepatitis C virus; TP: treponema pallidum; Ds-DNA: anti-double stranded DNA antibody; ANA: antinuclear antibodies; SS-B: anti-sicca syndrome B antibody; U1-NRnp: anti-U1 micronuclear ribonucleoprotein antibody; ARPA/Rib-P: anti-ribosomal P protein antibody; PCNA: anti-Proliferating cell antigen antibody; AMAM2: anti-mitochondrial antibody M2; CENPB: anti-centromere antibody; SS-A: anti-sicca syndrome A antibody; AnuA: anti-nucleosome antibody; AHA: anti-histone antibody; LKM: Anti-liver and kidney microsomal antibody; SLA: systemic lupus erythematosus; LP: anti-liver-pancreas antigen antibody; LC\_1: type I anti- hepatocyte solute antigen antibody; ACA: anti-cardiolipin antibody; NMDA: N-methyl-D-aspartic acid; AMPA: α-amino-3-hydroxy-5-methyl-4-isoxa-zolep-propionate; LGI1: leucine-rich glioma inactivated 1; CASPR2: contactin-associated protein 2; GABA: gamma aminobutyric acid; HOMER3: homer protein homolog 3; MBP: myelin basic protein; DPYSLS: dihydropyrimidinase-like proteins. AQP4: aquaporin-4; OB: oligoclonal bands. MRI: magnetic resonance imaging; EEG: electroencephalography. COI: cut off index; *-*, negative; *+*, positive.